Press Releases Investors Overview News / Events Overview Press Releases Publications IR Calendar Analyst Coverage Email Alerts Company Info Overview Management Team Clinical Advisory Board Medical Consultants Presentations Contacts FAQ Financial Info Overview Balance Sheet Income Statement Cash Flow Financial Results Stock Data Quote Charts Historical Data SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Investor Tools Email Alerts Tear Sheet Investor Presentation Contacts RSS News Feed News / Events Overview Press Releases Publications IR Calendar Analyst Coverage Email Alerts All Years 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 All Releases Financial Releases Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment Dec 20, 2018 Viveve Announces Closing of Public Offering of Shares of Common Stock Dec 11, 2018 Viveve Announces Pricing of Public Offering of Shares of Common Stock Dec 6, 2018 Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study Dec 6, 2018 Viveve Announces Proposed Public Offering of Shares of Common Stock Dec 6, 2018 Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders Nov 29, 2018 Viveve Named One of North America’s 500 Fastest Growing Companies by Deloitte Nov 15, 2018 Viveve to Present at Stifel 2018 Healthcare Conference Nov 8, 2018 Viveve Reports Third Quarter 2018 Financial Results Nov 8, 2018 Viveve to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results Nov 1, 2018 1... 3 4 5 6 7 8 9 10 11 12 ...31
Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study Dec 6, 2018
Viveve to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results Nov 1, 2018
